Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities.~* Male or female between 18 and 70 years of old.~* 19≤Body mass index(BMI)≤30kg/m\^2.~* No participate in any clinical trial at least 3 months.~* Diagnosed impaired fasting glucose(IFG) and impaired glucose tolerance(IGT) or Diabetes.~* In visit 1, 5.60mmol/L≤Fasting plasma glucose(FPG)\<8.0mmol/L; in visit 2, 6.1≤FPG\<8.0mmol/L or 7.8≤2-hour postprandial plasma glucose(2h-PPG) \<17mmol/L.~* Females in child-bearing period should be given birth control.~* No severe disease about heart, lung and kidney.~Exclusion Criteria:~* Type 1 diabetes~* Diabetes patients with previously treated or untreated FPG ≥ 8 mmol/L or 2-h PPG ≥ 17 mmol/L;~* Women of childbearing potential who are pregnant, breastfeeding or intend to become pregnant or are not using adequate contraceptive methods.~* Those who are allergic to study drugs~* Unable to cooperate~* Abnormal liver function, ALT and AST are more than 2 times of the normal upper limit~* Renal injury, blood creatinine ≥133 µmol/L~* Poor blood pressure control, systolic blood pressure SBP≥160mmHg and/or diastolic blood pressure DBP≥95mmHg~* Patients with chronic gastrointestinal diseases (pancreatitis, inflammatory bowel disease) and history of intestinal surgery~* Patients with severe heart disease, such as heart failure, unstable angina pectoris, acute myocardial infarction~* Chronic hypoxic diseases such as emphysema, pulmonary heart disease~* Having obvious diseases of the blood system~* Persons with tumor diseases~* Endocrine diseases, such as hyperthyroidism and hypercortisolism~* Mental illness, abuse of alcohol, drugs or other substances~* Persons with long-term oral or intravenous corticosteroid hormones therapy~* Having stress conditions such as surgery, severe trauma, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Berberine Hydrochloride group (Type: EXPERIMENTAL): 2/day, 16 weeks
- Bifidobacterium group (Type: EXPERIMENTAL): 2/day, 16 weeks
- Berberine Hydrochloride and Bifidobacterium group (Type: EXPERIMENTAL): 2/day, 16 weeks
- placebo (Type: PLACEBO_COMPARATOR): bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).